The WACC of Nectar Life sciences Ltd (NECLIFE.NS) is 16.6%.
Range | Selected | |
Cost of equity | 20.60% - 27.80% | 24.20% |
Tax rate | 21.90% - 33.00% | 27.45% |
Cost of debt | 11.00% - 15.40% | 13.20% |
WACC | 14.4% - 18.9% | 16.6% |
Category | Low | High |
Long-term bond rate | 6.9% | 7.4% |
Equity market risk premium | 8.3% | 9.3% |
Adjusted beta | 1.65 | 2.14 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 20.60% | 27.80% |
Tax rate | 21.90% | 33.00% |
Debt/Equity ratio | 1.04 | 1.04 |
Cost of debt | 11.00% | 15.40% |
After-tax WACC | 14.4% | 18.9% |
Selected WACC | 16.6% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for NECLIFE.NS:
cost_of_equity (24.20%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (1.65) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.